

Dabrafenib

Dabrafenib (sold under the brand name **Tafinlar**) is a serine/threonine kinase receptor inhibitor BRAF. It is approved for therapy of malignant melanoma with a proven mutation.

References

External Links

- European Medicines Agency. *Souhrn údajů o přípravku Tafinlar 50 mg tobolky* [online]. [cit. 12.3.2014]. <https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_cs.pdf>